|Evaluation of the Swedish adjustable gastric band VC (SAGB-VC) in an Australian population: early results.|
|PMID: 23187036 Owner: NLM Status: MEDLINE|
|BACKGROUND: The Swedish adjustable gastric band VC (SAGB-VC) has been in use in Australia since 2007. We evaluated its efficacy and safety.
METHODS: We retrospectively analyzed the prospective clinical data of patients who received the implant between November 2007 and June 2009 at 3 Australian bariatric centres.
RESULTS: In all, 1176 patients (mean age 45.9 [standard deviation (SD) 12.3] yr, mean body mass index 43.4 [SD 7.6]) received the SAGB-VC. At a mean follow-up of 11 (SD 3) months, weight reduced by a mean of 18.4 (SD 11.1) kg with an excess weight loss of 37.8% (SD 19.9%). Body mass index decreased (from mean 43.4 [SD 7.7] to mean 36.7 [SD 6.5], p < 0.001). Type 2 diabetes (T2DM) was reported in 167 patients and hypertension in 373. Improvement occurred in 73.5% of patients with T2DM and 31% with hypertension, with patient-reported reduction or cessation of medication. Metabolic syndrome indices improved during follow-up: high-density lipoprotein cholesterol (mean 1.3 [SD 0.3] v. mean 1.4 [SD 0.3] mmol/L, p < 0.001), triglycerides (mean 1.6 [SD 0.8] v. mean 1.3 [SD 0.7] mmol/L, p < 0.001), waist circumference (men 141 [SD 103] to 121 [SD 15] cm, women 117 [SD 14] to 105 [SD 14] cm, both p < 0.001), C-reactive protein (90.5 [SD 75.2] v. 53.3 [SD 61.9] nmol/L, p < 0.001). The complication rate was 4.2%.
CONCLUSION: The SAGB-VC is safe and effective for treating obesity and its comorbidities. The results are reproducible in separate Australian centres and consistent with published literature.
|Jennifer B Keogh; Anthony Brancatisano; Sue F Taylor; Fiona McDonald; Roy Brancatisano; Jeffrey M Hamdorf; Jacob Chisholm; Lillian Kow; Sara Wahlroos; Brendan Ryan; Jim Toouli|
Related Documents :
|10706836 - Transcranial doppler-directed dextran-40 therapy is a cost-effective method of preventi...
20339266 - Mechanical clot disruption following intravenous recombinant tissue plasminogen activat...
22365296 - Outcomes of percutaneous interventions for managing stenosis after meso-rex bypass for ...
22878516 - Clinical application of human adipose tissue-derived mesenchymal stem cells in progress...
15385346 - Peripherally inserted central catheters: a randomized, controlled, prospective trial in...
15088886 - Esthetic and dimensional evaluation of free connective tissue grafts in prosthetically ...
|Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't|
|Title: Canadian journal of surgery. Journal canadien de chirurgie Volume: 56 ISSN: 1488-2310 ISO Abbreviation: Can J Surg Publication Date: 2013 Feb|
|Created Date: 2013-01-28 Completed Date: 2013-03-17 Revised Date: 2013-04-12|
Medline Journal Info:
|Nlm Unique ID: 0372715 Medline TA: Can J Surg Country: Canada|
|Languages: eng Pagination: 15-20 Citation Subset: IM|
|The Australian Institute of Weight Control, Adelaide, Australia. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Biological Markers / blood
Blood Glucose / metabolism
Body Mass Index*
C-Reactive Protein / metabolism
Cholesterol, HDL / blood
Diabetes Mellitus, Type 2 / blood
Gastroplasty* / adverse effects, instrumentation, methods
Hypertension / complications, drug therapy
Insulin / blood
Metabolic Syndrome X / blood
Obesity, Morbid / complications, surgery*
Reproducibility of Results
Triglycerides / blood
|0/Biological Markers; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Insulin; 0/Triglycerides; 9007-41-4/C-Reactive Protein|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inhibiting inducible nitric oxide synthase with rutin reduces renal ischemia/reperfusion injury.
Next Document: Subbrachial approach to humeral shaft fractures: new surgical technique and retrospective case serie...